Advancing Intelligent Horizons Towards Brain Health
CINP-AsCNP 2025 Joint Congress

Keep up to dateNewsletter subscription

SubmissionsSubmit your symposium proposal

Join CINPBecome a member


Important dates

  • May 23, 2024

Symposia Submission OPEN Submit Symposium

  • September 30, 2024 at 23:59 CEST

Symposia Submission CLOSED

  • by November 15, 2024

Symposia Acceptance Notification

  • August 30, 2024

Abstract Submission OPEN

  • December 16, 2024

Abstract Submission CLOSED

  • February 7, 2025

Abstract Acceptance Notification

  • September 30, 2024

Registration OPEN

  • February 17, 2025


  • May 26, 2025 at 23:59 CEST

Standard Fee DEADLINE


Welcome to Melbourne!

We look forward to welcoming you to the World Congress of Neuropsychopharmacology as it returns to Australia for the first time in nearly 30 years. CINP-AsCNP 2025, the 36th World Congress, will be held at the Melbourne Convention and Exhibition Centre from Sunday, June 15th to Wednesday, June 18th, 2025, around the theme ‘Advancing Intelligent Horizons Towards Brain Health’. We plan to increase the opportunity for delegate interaction by incorporating a variety of new session formats and hope to combine scientific content of the highest quality with extensive networking opportunities and a memorable social and cultural experience.

With the development of science and technology in recent years, efforts to apply neuropsychopharmacology to clinical practice in neuropsychiatric disorders have flourished worldwide. There have been many important developments within Australia, which has developed a youth mental health paradigm and clinical staging for early psychosis including at risk states. Moreover, Australia is the first country to permit the use of psilocybin assisted therapy for treatment resistant depression and MDMA assisted therapy for post-traumatic stress disorder (July 2023) and has also pioneered trials in psilocybin assisted therapy for generalised anxiety disorder.

CINP-AsCNP2025 will bring together experts from research and medical institutions, leading worldwide regulatory authorities and major pharmaceutical firms to promote basic and clinical research and to create a framework for a cohesive collaboration between academia, industry and governmental institutions toward the development and appropriate use of central nervous system drugs. We are confident that, by fostering discussion between world leaders in neuropsychopharmacology and international expertise in related fields, the congress will lead directly to innovative developments in a wide range of fields associated with central nervous system drugs.
We invite you to be part of these discussions and to play your part in the development of our field!

CINP-AsCNP 2025 Co-Chair
Kazutaka Ikeda
Tokyo Metropolitan Institute of Medical Science
National Center of Neurology and Psychiatry
CINP President Elect
CINP-AsCNP 2025 Co-Chair
Suresh Sundram
Monash University
AsCNP President Elect